...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Prevention of in vivo lung tumor growth by prolonged local delivery of hydroxycamptothecin using poly(ester-carbonate)-collagen composites
【24h】

Prevention of in vivo lung tumor growth by prolonged local delivery of hydroxycamptothecin using poly(ester-carbonate)-collagen composites

机译:通过使用聚(碳酸酯)-胶原蛋白复合物延长羟基喜树碱的局部递送来预防体内肺肿瘤的生长

获取原文
获取原文并翻译 | 示例
           

摘要

Local tumor recurrence has a major impact on long-term patient survival following the surgical treatment of most cancers, and this is especially true with lung cancer. Consequently, methods to deliver chemotherapeutics locally at a lung tumor resection margin would be beneficial since: 1) systemic treatment approaches are ineffective or highly toxic; 2) the incidence of local recurrence does not warrant universal treatment of all patients with a highly morbid systemic therapy; and 3) surgical resection of recurrent disease is not an option and alternative rescue therapies are generally unsuccessful. To begin to meet this clinical need, we have prepared poly(glycerol monostearate-co-ε-caprolactone) films as a controlled, prolonged, and low dose delivery matrix for the potent anticancer agent 10-hydroxycamptothecin (HCPT). These drug-loaded films were applied to a collagen-based scaffold clinically indicated for the mechanical buttressing of lung tissue following surgical resection, resulting in a flexible composite that can be secured to the tissue that releases HCPT over seven weeks and thereby prevents the local growth and establishment of Lewis lung carcinoma tumors in vivo (a freedom of local tumor growth of 86%). In comparison, all animals treated with a larger intravenous dose of HCPT or unloaded composites developed rapid local tumors.
机译:大多数癌症的手术治疗后,局部肿瘤的复发对长期患者的生存有重大影响,对于肺癌尤其如此。因此,在肺肿瘤切除边缘处局部递送化学治疗剂的方法将是有益的,因为:1)全身治疗方法无效或剧毒。 2)局部复发的发生率并不能保证对所有患者采用高度病态的全身疗法进行普遍治疗;和3)手术切除复发性疾病是不可行的,替代性的抢救疗法通常是不成功的。为了开始满足这一临床需求,我们准备了聚(单硬脂酸甘油酯-ε-己内酯)薄膜,作为有效的抗癌剂10-羟基喜树碱(HCPT)的受控,延长剂量和低剂量给药基质。将这些载有药物的薄膜应用于临床表明可用于外科手术切除后肺组织机械支撑的胶原基支架上,从而形成一种可固定在组织上的柔性复合材料,该复合材料可在七周内释放HCPT,从而防止局部生长和体内建立Lewis肺癌肿瘤(局部肿瘤生长的自由度为86%)。相比之下,所有以较大剂量的HCPT或未加复合物静脉注射治疗的动物均出现快速局部肿瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号